Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
Can You Take Blood Thinners With Cancer Drugs Safely?
This retrospective analysis at Hunan Cancer Hospital assessed 208 patients receiving concurrent anti-VEGF agents and anticoagulants for VTE.
New research suggests it is generally safe to use blood thinners with certain cancer treatments.
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.